Respiratory tract infections (RTIs) are a persistent public health problem and include a series of clinical syndromes covering the common cold, influenza, and other upper and lower respiratory tract infections (URTIs and LRTIs, respectively).

RTIs are still among the primary causes of death worldwide, despite the remarkable advances in antibiotic therapies, diagnostic tools, and intensive care.

Influenza viruses affect up to 20% of the world’s population each year.

Acute respiratory infections are associated with almost 50% of hospitalizations in children; it is estimated that respiratory tract infection causes nearly 4 million deaths annually and is a leading cause of death among children under 5 years old.

Incorrect antibiotic therapy is prescribed in 30 to 50% of the cases increasing the risk of multi-resistances species.

CRL 1505™ reduces the incidence of upper respiratory tract and gastrointestinal infections, supporting the immune system and reduces the need for antibiotics consumption.

Lacticaseibacillus rhamnosus CRL 1505™

The immunobiotic

CRL 1505™ reduces the incidence of upper respiratory tract and gastrointestinal infections, supporting the immune system and reduces the need for antibiotics consumption.

Hypoallergenic  Vegetarian  Gluten free
Kosher  Halal
GMO free  Genome Sequenced  Gastric resistant

Contact us to know product’s availability in your market

Saccosystem.com

Supporting food cultures and life since 1872
CRL 1505™ boosts the immune system

The mechanisms of action of CRL 1505™ have been unveiled in a series of in vivo models, and include increased basal levels of interferon gamma (IFN-γ) in the host, a key activator of the innate and adaptive immune system, and of the anti-inflammatory cytokine interleukin 10 (IL-10). These modulations allow the priming of the immune system to tackle RTIs through an overall stimulation of the immune system, intra- and extra-intestinally [2].

One of the key elements identified in CRL 1505™ interaction with the host is its strain-specific peptidoglycan (PG05), which has proven to have a immunomodulatory activity. PG05 significantly increases specific antibodies production and the number of alveolar macrophages (AMs) producing interferon beta (IFN-β). These cells play a key role in the beneficial modulation of the respiratory innate immune response during viral and bacterial infections [6-7].

CRL 1505™ reduces URT infections

Reduces infections

Boosts the immune system

<table>
<thead>
<tr>
<th>Human trial</th>
<th>Placebo</th>
<th>CRL 1505™</th>
</tr>
</thead>
<tbody>
<tr>
<td>percentage</td>
<td>50</td>
<td>60</td>
</tr>
</tbody>
</table>

Reduces infections:

- Pharyngitis and tonsillitis
- Diarrhea

Boosts the immune system:

- Interferon gamma (IFN-γ)
- Interleukin 10 (IL-10)

Protects from bacterial infections

Protects from viral infections

CRL 1505™ facts

- More than 35 publications in pre-clinical and clinical studies
- Scientifically demonstrated ability to keep viral and bacterial respiratory tract infections at bay
- Clinically proven reduction of upper respiratory and gastrointestinal infections
- Every day 350,000 children in Argentina benefit of the immunological properties of CRL 1505™ which is part of the official National Nutritional Program

References:

1. Wang Y et al., Medicine (Baltimore) 95(31), e4509 (2016)